



Adjuvanted Influenza Vaccines

Guest Editors:

Dr. Eduardo Gomez-Casado

Department of Biotechnology,
INIA-CSIC, 28040 Madrid, Spain

Dr. Dheeraj Soni

Boston Children's Hospital,
Harvard Medical School, Boston,
MA, USA

Deadline for manuscript
submissions:

closed (20 February 2022)

Message from the Guest Editors

One approach to improving influenza vaccines is to include adjuvants. An immunologic adjuvant is defined as a substance that acts to accelerate, prolong, or enhance antigen-specific immune responses when used in combination with specific vaccine antigens. Adjuvants are particularly beneficial for influenza vaccines administered during a pandemic, when a rapid response is required or for use in patients with impaired immune responses. To date, six adjuvants have been used in licensed human vaccines: Alum, MF59, AS03, AF03, virosomes, and heat-labile enterotoxin (LT).

This issue will address the potential of novel adjuvant strategies to modulate innate and adaptive immune responses to facilitate the development of improved prophylactic or therapeutic vaccines. Submission of original articles and systematic reviews is welcome. Manuscripts will follow standard journal peer-review practices, and those accepted for publication will appear in the Special Issue, "Adjuvanted Influenza Vaccines". We look forward to receiving and welcome your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com